HR Execs on the Move


 
Alcami is a contract development and manufacturing organization headquartered in North Carolina with over 40 years of experience advancing products through every stage of the development lifecycle. Alcami serves pharmaceutical and biotech companies of all sizes for small molecules and biologics, providing customizable and innovative solutions for analytical development, clinical to commercial sterile and oral solid dose drug product manufacturing, packaging, microbiology, cGMP biostorage, environmental monitoring, and pharmaceutical support services. Alcami`s private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.alcami.com
  • 2320 Scientific Park Drive
    Wilmington, NC USA 28405
  • Phone: 910.254.7000

Executives

Name Title Contact Details
Shelley Brinkley
Senior Director, Talent Profile
Gerry Glennon
Vice President of Global Supply Chain Profile
Rose-Marie Nelson
EVP, Talent Acquisition, Benefits and Profile
Rose-Marie Nelson
Chief Human Resources Officer Profile
Shelley Brinkley
Director Talent Acquisition Profile

Similar Companies

Wilshire Labs

Wilshire Labs is a pharmaceutical company based in Pakistan that manufactures and markets innovative and quality medicines, which help prevent, cure and alleviate illnesses as well as save lives while serving the best interest of consumers and employees.

EQRx

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines.

Aeryon Labs Inc

Aeryon Labs Inc is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

HumanCo

HumanCo is a mission-driven private holding company that invests in and builds brands focused on healthier living and sustainability.

Pliant Therapeutics

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant`s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.